Emergent BioSolutions (EBS) Misses Q3 EPS by 3c, FY Revenue Guidance Beats

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Emergent BioSolutions (EBS) Misses Q3 EPS by 3c, FY Revenue Guidance Beats

Goldman Sachs Upgrades Emergent BioSolutions (EBS) to Buy

November 2, 2018 4:29 AM EDT

Goldman Sachs analyst Dana Flanders upgraded Emergent BioSolutions (NYSE: EBS) from Neutral to Buy with a price target of $75.00 (from $60.00).

The analyst believes a premium valuation is warrant due to the company's "sticky and growing" base business which has high barriers to entry.... More